Nanobiotix SA(NBTX.US)

Last Updated 19:00:00 ET
longbridge loading

Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer

Tip Ranks·
US
NBTX
-6.63%
Tip Ranks·
US
NBTX
-6.63%

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | NBTX Stock News

StockTitan·
US
NBTX
-6.63%
US
FBT
+0.54%
US
SBIO
-1.24%
StockTitan·
US
NBTX
-6.63%
US
FBT
+0.54%
US
SBIO
-1.24%

Nanobiotix (NASDAQ:NBTX) Hits New 1-Year High - Here's What Happened

Market Beat·
US
NBTX
-6.63%
Market Beat·
US
NBTX
-6.63%

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study | NBTX Stock News

StockTitan·
US
NBTX
-6.63%
US
SBIO
-1.24%
US
ARKG
+0.04%
StockTitan·
US
NBTX
-6.63%
US
SBIO
-1.24%
US
ARKG
+0.04%

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Sees Significant Decline in Short Interest

Market Beat·
US
NBTX
-6.63%
US
IBB
+0.10%
US
LABU
-2.35%
Market Beat·
US
NBTX
-6.63%
US
IBB
+0.10%
US
LABU
-2.35%

Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating

Tip Ranks·
US
JNJ
+0.47%
US
NBTX
-6.63%
US
IBB
+0.10%
Tip Ranks·
US
JNJ
+0.47%
US
NBTX
-6.63%
US
IBB
+0.10%
© 2026 Longbridge｜Disclaimer